Cancer
Puma Biotech’s breast cancer drug authorised by European Commission, despite prior concerns
September 5, 2018Research and Development Cancer, EU, breast cancer, ec approval, puma biotechnology
Puma Biotechnology have received European Commission marketing authorisation for Nerlynx (neratinib) despite prior concerns as to the safety and efficacy …
Widening the focus on innovations in cancer treatment
September 3, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 23andME, CRUK, Cancer, GSK, diagnosis, genetics, oncology, pharma
Cancer treatment is making leaps and bounds, but public focus tends to gravitate towards the therapies themselves. Matt Fellows explores …
The September 2018 issue of Pharmafocus is available to read online now!
September 3, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, AstraZeneca, Cancer, Iraw, J&J, JJ, Pfizer, Roche, UK, brexit, drug safety, pharma, pharmacovigilance
The new September edition of Pharmafocus is now live and available to read online. We’re entering the final stretch as …
AI used to forecast cancer progression
September 3, 2018Sales and Marketing AI, Cancer, ICR, London, ai drug research and development, university of edinburgh
A team of scientists at the Institute of Cancer Research (ICR) in London and the University of Edinburgh have developed …
Shire hands over its oncology franchise to Servier for $2.4bn
August 31, 2018Medical Communications, Sales and Marketing Cancer, Servier, Shire, oncology, pharma, sale
Shire has completed the sale of its oncology franchise to French firm Servier for $2.4 billion, handing over the global …
Novartis’ Kymriah & Gilead’s Yescarta become first EU-approved CAR T therapies
August 28, 2018Manufacturing and Production, Sales and Marketing CAR T, CAR-T, Cancer, EU, Gilead, Kymriah, Novartis, UK, Yescarta, blood cancer, pharma
Almost one full year since the treatment was given a “historic” approval in the US, Novartis’ CAR T therapy Kymriah …
Novartis’ investigational combo impresses in breast cancer sub-group
August 23, 2018Research and Development Cancer, Novartis, breast cancer, fulvestrant, pharma
Novartis has revealed positive new data for its investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) combined with fulvestrant in the treatment …
Japan approves AstraZeneca’s Tagrisso in EGFRm non-small cell lung cancer
August 21, 2018Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, Japan, Tagrisso, lung cancer, pharma
AstraZeneca has revealed that its EGFR tyrosine kinase inhibitor Tagrisso (osimertinib) has been approved in Japan by the nation’s Ministry …
Chinese regulators approve Roche’s Alecensa in regulatory shift
August 20, 2018Sales and Marketing Cancer, China, Roche, approval, lung cancer
China’s National Drug Administration has granted rapid approval for Roche’s lung cancer treatment Alecensa (alectinib). Chinese regulators have in the …
“Radical radiotherapy” cuts required treatments from 37 to 5
August 14, 2018Manufacturing and Production Cancer, oncology, pharma, radiotherapy
Researchers at Queen’s University Belfast have been trialling a new form of “radical radiotherapy” which can be delivered in just …
Rare lung cancer drug approved in Scotland
August 14, 2018Manufacturing and Production Cancer, SMC, Scotland, Scottish Medicines Consortium, approval, lung cancer
The Scottish Medicines Consortium has approved Roche’s cancer drug alectinib for the treatment of patients with untreated advanced non-small-cell lung …
NHS scraps restriction on availability of J&J’s Imbruvica in leukaemia patients
August 10, 2018Medical Communications, Sales and Marketing Cancer, J&J, JJ, Johnson & Johnson, NHS, NICE, UK, imbruvica, leukaemia, pharma
The NHS has dropped a controversial restriction preventing leukaemia patients from accessing Johnson & Johnson’s tyrosine kinase inhibitor Imbruvica (ibrutinib), …
Regeneron Pharma and Bluebird bio announce immune cell collaboration
August 6, 2018Sales and Marketing Cancer, Regeneron, Shares, bluebird, collaboration, t cells, t-cells
Regeneron Pharmaceuticals have announced that they will collaborate with the Massachusetts-based gene therapy specialist Bluebird bio in an effort to …
Novartis hands over global rights for two oncology drugs to Shanghai’s Laekna
August 2, 2018Sales and Marketing Cancer, Laekna, Novartis, oncology, pharma
Novartis has revealed that it has jettisoned two of its clinical stage oncology products along with exclusive global development and …
Biosimilars and generics saved NHS £324m last year
August 2, 2018Medical Communications, Sales and Marketing Cancer, NHS, biosimilars, funding, generics
The NHS watchdog, NHS Improvement, has revealed that the British National Health Service saved £324 million last financial year by …
Latest content
Five Facts about cardiovascular disease
